2023 - Research.com Medicine in Japan Leader Award
2023 - Research.com Immunology in Japan Leader Award
2022 - Research.com Best Scientist Award
2022 - Research.com Medicine in Japan Leader Award
2022 - Research.com Immunology in Japan Leader Award
Hideo Yagita mostly deals with Immunology, Cell biology, T cell, Cancer research and Cytotoxic T cell. His Immunology study is mostly concerned with Tumor necrosis factor alpha, Immune system, Natural killer T cell, Monoclonal antibody and Antigen. His Cell biology research includes elements of Cell, Antigen-presenting cell, Apoptosis, Dendritic cell and CD28.
His T cell research is multidisciplinary, relying on both T lymphocyte, Immune tolerance and FOXP3. The concepts of his Cancer research study are interwoven with issues in Natural killer cell, Interferon gamma, Pathology, TRAF2 and Immunotherapy. Hideo Yagita has researched Cytotoxic T cell in several fields, including Molecular biology, CD8 and Fas ligand.
The scientist’s investigation covers issues in Immunology, Cell biology, T cell, Cytotoxic T cell and Cancer research. His Immunology and Immune system, Antigen, CD8, Antibody and Tumor necrosis factor alpha investigations all form part of his Immunology research activities. Hideo Yagita combines subjects such as Receptor, Cell and CD40 with his study of Cell biology.
His T cell research is multidisciplinary, incorporating perspectives in Blockade and T lymphocyte. Within one scientific family, Hideo Yagita focuses on topics pertaining to Molecular biology under Cytotoxic T cell, and may sometimes address concerns connected to T-cell receptor and CD3. He works mostly in the field of Cancer research, limiting it down to topics relating to Apoptosis and, in certain cases, Cell culture, as a part of the same area of interest.
Immunology, Cancer research, Immune system, T cell and Cytotoxic T cell are his primary areas of study. His Immunology research focuses on subjects like Blockade, which are linked to Melanoma. Hideo Yagita interconnects Cancer, Colorectal cancer, Immunotherapy and Notch signaling pathway in the investigation of issues within Cancer research.
As a part of the same scientific family, Hideo Yagita mostly works in the field of Immune system, focusing on Antibody and, on occasion, Molecular biology, Microfold cell and Antigen. His work deals with themes such as CD80, CD40 and Cell biology, which intersect with T cell. His Cell biology research integrates issues from Receptor and Bone marrow.
His scientific interests lie mostly in Immunology, Cancer research, Cytotoxic T cell, T cell and Immune system. His Immunology study combines topics from a wide range of disciplines, such as Apoptosis and Blockade. The various areas that Hideo Yagita examines in his Cancer research study include Flow cytometry, Lesion, Immunogenicity, Macrophage and Notch signaling pathway.
His Cytotoxic T cell research includes themes of CD86 and CD8. His studies deal with areas such as Interleukin 12, Antigen and Cell biology as well as T cell. His Cell biology study incorporates themes from Secretion and Gene expression profiling.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Yasutoshi Agata;Akemi Kawasaki;Hiroyuki Nishimura;Yasumasa Ishida.
International Immunology (1996)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran;Welby Montalvo;Hideo Yagita;James P. Allison.
Proceedings of the National Academy of Sciences of the United States of America (2010)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R. Simpson;Fubin Li;Welby Montalvo-Ortiz;Manuel A. Sepulveda.
Journal of Experimental Medicine (2013)
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Tomohide Yamazaki;Hisaya Akiba;Hideyuki Iwai;Hironori Matsuda.
Journal of Immunology (2002)
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
Takeo Nomi;Masayuki Sho;Takahiro Akahori;Kaoru Hamada.
Clinical Cancer Research (2007)
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Yuichiro Ohigashi;Masayuki Sho;Yukishige Yamada;Yoshikazu Tsurui.
Clinical Cancer Research (2005)
New aspects of natural-killer-cell surveillance and therapy of cancer
Mark J. Smyth;Yoshihiro Hayakawa;Kazuyoshi Takeda;Hideo Yagita.
Nature Reviews Cancer (2002)
ATP drives lamina propria T H 17 cell differentiation
Koji Atarashi;Junichi Nishimura;Tatsuichiro Shima;Yoshinori Umesaki.
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
Madhav D. Sharma;Babak Baban;Phillip Chandler;De Yan Hou.
Journal of Clinical Investigation (2007)
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice.
Mohammed Javeed I. Ansari;Alan D. Salama;Alan D. Salama;Tanuja Chitnis;Tanuja Chitnis;R. Neal Smith.
Journal of Experimental Medicine (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: